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Abstract
Background: An early diagnostic test for detecting infection in leprosy is fundamental for reducing patients’
sequelae. The currently used lepromin is not adequate for disease diagnosis and, so far, no antigen to be used in
intradermoreaction has proved to be sensitive and specific for that purpose. Aiming at identifying new reagents to
be used in skin tests, candidate antigens were investigated.
Methods: Random peptide phage display libraries were screened by using antibodies from leprosy patients in
order to identify peptides as diagnostic reagents.
Results: Seven different phage clones were identified using purified antibodies pooled from sera of leprosy
patients. When the clones were tested with serum samples by ELISA, three of them, 5A, 6A and 1B, allowed
detecting a larger number of leprosy patients when compared to controls. The corresponding peptides expressed
by selected phage clones were chemically synthesized. A pilot study was undertaken to assess the use of peptides
in skin tests. The intradermal challenge with peptides in animals previously sensitized with Mycobacterium leprae
induced a delayed-type hypersensitivity with peptide 5A (2/5) and peptide 1B (1/5). In positive controls, there was a
3/5 reactivity for lepromin and a 4/5 reactivity of the sensitized animals with soluble extract of M. leprae.
Conclusions: The preliminary data suggest that may be possible to develop reagents with diagnostic potential
based on peptide mimotopes selected by phage display using polyclonal human antibodies.
Background
Leprosy is a chronic granulomatous infectious disease
caused by M. leprae that affects the skin and the periph-
eral nervous system [1]. This disease constitutes a public
health problem in countries such as Brazil [2], where
large numbers of patients with sequelae as a result of
neural damages are still observed every year [3]. Upon
the introduction of multidrug therapy in 1981 by the
WHO, the prevalence of leprosy has been dramatically
reduced, but over the last 5 years, more than 200,000
new cases have been detected each year [4]. These more
recent data indicate that the transmission of leprosy still
goes on [5], which makes it clear that new strategies -
besides treatment - are necessary to eliminate the
disease as a public health problem.
Leprosy presents a wide range of clinical manifestations
determined by the immune response of the individual
against the bacillus. Tuberculoid leprosy patients show a
response that limits pathogen growth and result in few
lesions containing rare (or absence of) bacilli however,
nerve damage is often present. Lepromatous leprosy
patients are susceptible to disseminated infection. Skin
lesions are numerous and there is an uncontrolled
proliferation of leprosy bacilli. Such clinical presentations
correlate to the level of cell-mediated immunity (CMI)
against M. leprae. Antibody responses are greater in lep-
romatous patients, indicating that humoral immunity does
not contribute to host defense [6].
The delayed-type hypersensitivity reaction (DTH) in
skin tests is considered a manifestation of the cell-mediated
immunity [2]. In leprosy, cells of M. leprae from different
origins and submitted to different processes of purification
are the basis for different types of preparations employed
in skin tests. Among those preparations, the most
frequently used is lepromin, which corresponds to a
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suspension of heat-killed bacilli [7]. As M. leprae is
not cultivated in vitro, cells for lepromin preparation
can only be obtained from naturally infected human
tissues (lepromas) or from experimentally infected
armadillos [8].
Two types of positive skin reactions are described after
the intradermal injection of 0.1 mL of lepromim: an
early reaction (Fernandez Reaction), read after 48–72 -
hours; and a late reaction (Mitsuda Reaction), read after
3–4 weeks [9]. The Mitsuda reaction is measured as in-
duration and provides a measure of the individual’s
ability to mount a granulomatous response against
mycobacterial antigens [7]. Positive Mitsuda reactions are
seen in the vast majority of contacts and unexposed
individuals, as well as in tuberculoid leprosy patients; in
leprosy patients with lepromatous disease no response is
observed. Therefore, reactivity to lepromin can not used
for diagnosis, but has a prognostic value [9]. In Brazil, the
Centro de Produção e Pesquisa de Imunobiológicos (CPPI)
is the only supplier of lepromin antigen for the Brazilian
Department of Health, and its production is based on
lepromas obtained from lepromatous leprosy patients.
This is a difficult process because the production of
the antigen depends on access to rare lepromas that
may be contaminated with other species of mycobac-
teria [10]. In addition, the strategy is associated with
the risk of manipulation and inoculation of human
biological material.
An alternative for replacing whole cells or purified
fractions of M. leprae is to use synthetic peptides. Previ-
ous studies have demonstrated delayed-type hypersensi-
tivity responses to peptides in skin tests [11,12]. Aiming
at finding alternative diagnostic supplies for leprosy,
peptides binding antibody from multibacillary leprosy
patients were selected from phage displayed peptide
libraries and assessed in their capacity to induce cell
response in guinea-pigs sensitized with M. leprae.
Methods
Antigens
The M. tuberculosis H37Rv (ATCC 27294) strain was
obtained from the Instituto Adolfo Lutz, São Paulo - Brazil.
The cells were grown in Middlebrook 7H10 for 14–21 days
at 37C, followed by suspension in 0.9% NaCl and inactiva-
tion at 100C for 15 minutes. Irradiated M. leprae whole
cells isolated from armadillo liver were kindly supplied
by Dr. J. S. Spencer from Colorado State University
(Fort Collins-USA) through the National Institute of
Allergy and Infectious Diseases/National Institutes of
Health under contract N01-AI-25469. Bacilli in 0.9%
NaCl containing 100 μg/mL phenylmethylsulfonyl fluoride
(PMSF) and 2 mM ethylenediaminetetraacetic acid (EDTA)
were broken by sonication (Sonopuls HD 2200, Bandelin,
Berlin-Germany) four cycles of 15 minutes [13]. Following
lysis, the soluble fraction was separated by centrifugation at
10000 × g for 20 minutes at 4C, and the protein concen-
tration was determined using the Quant-iT Protein Assay
kit (Invitrogen, California-USA).
Patient serum samples
Serum samples of 10 paucibacillary patients (PB), 23
multibacillary patients (MB), and 26 household contacts
were obtained. The samples were collected at the Hospital
de Dermatologia Sanitária (Piraquara, Paraná-Brazil),
Centro Regional de Especialidades-Barão (Curitiba, Paraná-
Brazil), Fundação Pró-Hansen (Curitiba, Paraná-Brazil),
and at Sociedade Filantrópica Humanitas (São Jerônimo da
Serra, Paraná-Brazil). Among the leprosy patients, 14 had
not yet started the treatment by the time of blood collec-
tion, and 19 were under treatment (days - 4 months).
Serum of 30 patients with pulmonary tuberculosis (TB) -
under treatment (days - 3 months) - was obtained at the
Centro Regional de Especialidades-Barão (Curitiba, Paraná-
Brazil) and at the Hospital Regional da Lapa ‘São Sebastião’
(Lapa, Paraná-Brazil). Leprosy and TB patients were
diagnosed and classified by a specialized physician at
the Health Units. Serum of 30 endemic controls was
obtained from volunteers with no history of infection by
leprosy and tuberculosis. In all cases, drawing of blood
was carried out with informed consent and approved by
the Research Ethics Committee of Federal University of
Paraná (Comitê de Ética em Pesquisa, Setor de Ciências
da Saúde, Universidade Federal do Paraná).
Immunoglobulins anti-M. leprae and anti-M. tuberculosis
IgG of the sera pool from MB patients were obtained by
precipitation with ammonium sulfate followed by chro-
matography using protein G-agarose [14]. The anti-M.
leprae IgGs were recovered from immunoblots. For that,
the M. leprae protein extract was resolved by SDS-
PAGE in gradient polyacrylamide gel 10-20%; after
having been transferred to the PVDF membrane, IgGs
binding antigen immobilized in membrane were eluted
with 0.1 M glycine, 0.15 M NaCl, pH 2.8 at room
temperature for 30 minutes. Anti-M. leprae IgGs were
dialyzed against PBS after neutralization with 1 M Tris–
HCl, pH 9.0, and the protein concentration was
determined by the Bradford method [15]. The same
process was repeated using a sera pool from tuberculosis
patients and M. tuberculosis protein in order to obtain
anti-M. tuberculosis antibodies.
Screening of random peptide phage display libraries
Linear (X15 and X8CX8) and constrained (XCX4CX and
XCX8CX) random peptide libraries were obtained from
J. Scott, Simon Fraser University (Burnaby BC-Canada).
Peptides are expressed on the surface of protein pVIII of
phage f88.4. Two panning strategies were used. In
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strategy I, the phages of libraries not bound to anti-M.
tuberculosis immunoglobulins immobilized in immunotube
were used in the first round of panning with anti-M.
leprae immunoglobulins. In strategy II, the phages of li-
braries were directly used in the first round of panning
with anti-M. leprae immunoglobulins. Panning was carried
out according to the previously given description [16].
Briefly, one immunotube (Nunc, Roskilde-Denmark) was
coated with anti-M. leprae immunoglobulin in 100 mM
NaHCO3, pH 8.6 at 5 μg/1.5 mL and incubated overnight
at 4C. The immunotube was washed with TBST-0.05%
(TBS Tween 20–0.05%), filled with blocking solution
(TBST-0.05%, 3% BSA) and incubated for 2 hours at 37C.
For the first round of panning, 1.5 × 1011 phages of libraries
X15 and XCX8CX, and 2.5 × 1010 phages of libraries
X8CX8 and XCX4CX were incubated in TBST-0.05% with
the immobilized antibodies. After the washings with TBST-
0.5%, the bound phages were eluted with 1.5 mL 0.1 M gly-
cine, pH 2.2, 1 mg/mL BSA. After neutralization with 2 M
Tris–HCl, pH 9.0, the eluted phages were amplified by
infecting a culture of E. coli K91. After incubation overnight
at 37C, the supernatant was obtained and precipitated
with PEG/NaCl. In the remaining rounds, 2 × 1011 ampli-
fied phages of the previous cycle were incubated with IgG
anti-M. leprae. The procedures were equal to those
applied to the first round except for the fact that the
concentration of the antibody immobilized to the
immunotube was 1 μg and 0.5 μg in the second and
subsequent rounds, respectively.
Immunological screening of phage clones
After four rounds of panning, individual colonies
containing phages were picked at random and grown
overnight at 37C in a 96-well microtiter plates in LB
medium containing 20 μg/mL tetracycline. The plates
were centrifuged (1600 × g, 20 minutes) and supernatant
containing phages was analyzed regarding its binding to
IgG from leprosy patients by ELISA. Microtiter plates
(Falcon, BD Biosciences, California-USA) were coated by
incubating 50 μL anti-phage antibody (Sigma-Aldrich,
Missouri-USA) diluted 1:800 in 100 mM NaHCO3,
pH 8.6, overnight at 4C. The plates were washed with
PBST-0.05% and blocked with 2% skimmed milk powder
in PBST-0.05% for 1 hour at 37C. The supernatant of
each phage clone was added to each microtiter well. As a
negative control, the supernatant of the E. coli K91 culture
was used. After incubation for 2 hours at 37C, the plate
was washed and incubated with 100 μg/mL IgG for 1 hour
at 37C. After washing, peroxidase conjugated anti-
human antibody (Sigma-Aldrich, Missouri-USA) - diluted
1:10000 in a blocking solution for 1 hour at 37C -
was added. After washing, bound antibodies were
monitored for determining the peroxidase activity using
ο-phenylenediamine dihydrochloride (OPD) (Sigma-
Aldrich, Missouri-USA) as chromogen for measuring ab-
sorbance at 492 nm. The most reactive clones (absorbance
at least twice as high as the negative control) were selected
for DNA sequencing and subsequent identification of the
peptide sequence inserted into the phages.
Determination of peptide sequences
Single-stranded DNA was prepared out of phage clones
using QIAprep Spin M13 kit (Qiagen, Hilden-Germany).
Peptide sequences of the positive phage clones were
determined by the BigDye Terminator v3.1 kit (Applied
Biosystems, California-USA) using the reverse primer
50-TCGGCAAGCTCTTTTAGG-30.
Phage-ELISA
Reactivity of the phage clones most reactive in the pres-
ence of human serum was measured by ELISA according
to description given above. Microtiter plates were coated
with anti-phage antibody and incubated with 2 × 1010
phages/mL followed by the addition of sera from leprosy
patients, tuberculosis patients, household contacts of
leprosy patients, and endemic controls, diluted 1:100.
The detection of the reaction was performed with
peroxidase conjugated anti-human antibody and OPD
as chromogen.
Synthetic peptides
Peptides were synthesized using solid phase 9-
fluorenilmetoxycarbonyl (Fmoc) chemistry by PepTron
(Daejon-Korea). Peptide purity was equal to or higher
than 70%.
Guinea pigs and delayed-type hypersensitivity responses
The experiments with these animals followed the
guidelines of Brazilian College of Animal Experimentation
(Colégio Brasileiro de Experimentação Animal - COBEA)
and were approved by the institutional committee of
Federal University of Paraná.
Three groups of five 250–300 g outbred female guinea
pigs (Cavia porcellus) were used for the skin test. The
antigens were diluted in 0.9% NaCl. The Mitsuda
lepromin (4x107 bacilli/mL) provided by the Centro de
Produção e Pesquisa de Imunobiológicos (Piraquara,
Paraná-Brazil) was used as positive control, and 0.9%
NaCl was used as negative control. Five animals (group
I) were sensitized by subcutaneous inoculation of 200 μg
[17] of M. leprae in Freund’s incomplete adjuvant
(Sigma-Aldrich, Missouri-USA). As control, five animals
(group II) received 0.9% NaCl in Freund’s incomplete
adjuvant subcutaneously. Control group III consisted
of non-sensitized animals. After 30 days, each animal
received, intradermally, 0.1 mL of the antigens: peptides
(10 and 2 μg), peptide pool (10 and 2 μg), Mitsuda
lepromin (positive control), soluble extract of M. leprae
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(10 μg, positive control) and 0.9% NaCl (negative control).
The diameter of the skin reaction was measured after 24,
48, and 72 hours, 21 and 28 days.
Bioinformatics
The peptide sequences were analyzed for sequence simi-
larity using FASTA program on M. leprae sequence data
(http://genolist.pasteur.fr/Leproma/).
Results and discussion
In order to identify mimotopes of mycobacterial antigens,
peptide libraries displayed by phage were selected by affin-
ity using M. leprae antigen-specific antibodies. The anti-
bodies were obtained from a pool of sera from MB
patients. The IgGs were purified by ammonium sulfate
precipitation and affinity chromatography followed by elu-
tion from membranes containing M. leprae antigens
bound. The total IgGs from MB patients recognized
proteins in M. leprae especially below 50 kDa (Figure 1B,
lane 1). The same profile of reactivity was seen with
antigen-specific IgGs (Figure 1B, lane 2), however, the
antibody preparation method represent an important
purification and concentration step, as relatively specific
antibodies are purified from total IgG well as most of
the extraneous IgGs active against other antigens are
removed. Lipoarabinomannan (LAM) is a major antigen
of M. leprae that is recognized by immunoglobulins in
sera from leprosy patients [18] and runs as a broad diffuse
band from 30–40 kDa as shown in Figure 1.
Two panning strategies were used. In one of them, the
phage pool with anti-M. leprae antibodies, was depleted
of reactive phages with anti-M. tuberculosis antibodies.
Four rounds of affinity selection were performed and the
amplified phage pool of each selection round was
assessed by ELISA (Figure 2). In both strategies, an in-
crease of reactivity was observed with each round of
panning. However, the best result was detected between
the phages and the IgG obtained in strategy II.
The phage pool of the last selection round was then
chosen to isolate individual positive clones. Each phage
clone was assessed – by ELISA – regarding its ability to
bind to IgG of multibacillary patients. In strategy I, 24
out of 400 clones analyzed showed recognition against
patients’ antibodies, and 6 different peptide sequences
were identified. In strategy II, 36 out of the 342 clones
were recognized for binding to antibodies against
leprosy and all expressed an identical sequence of 15
aminoacids.
The respective phage clones carrying the identified
peptide sequences were then assessed against sera of lep-
rosy patients and controls by ELISA (Figure 3). Reactive
control samples were the same regardless of the assessed
clones, which could indicate an unspecific reaction
between serum and phages.
Figure 1 SDS-PAGE and Western blot analysis of total extract
of M. leprae. A. Twenty micrograms of total extract of M. leprae
were separated by 10-20% gradient SDS-PAGE and the gel was
stained with silver nitrate (lane 2). Molecular weight marker is shown
in the lane 1. B. The proteins were transferred to PVDF membrane
and blots were probed with 1 μg/mL of MB patients’ total IgG
(lane 1), 60 ng/mL of MB patients’ antigen-specific IgG (lane 2) and
1 μg/mL of PB patient’ total IgG (lane 3). Detection of the reaction
was performed with anti-human IgG (Fc-specific)-peroxidase



















Strategy I Strategy II
Negativo 1 round 2 round 3 round 4 round
control
Figure 2 Reactivity of phages pools selected by affinity
strategies at each selection round by ELISA. Microtiter plate was
coated with anti-phage antibody (1:800) and incubated with 2 × 1010
phages/mL followed by the addition of IgG (100 μg/mL). The
detection of the reaction was performed with peroxidase
conjugated anti-human antibody and OPD as chromogen. Values of
absorbance at 492 nm are means of duplicates. Wild phage was
used as negative control.
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Seven phage clones were selected and, among them,
clones 5A, and 6A, clones isolated by strategy I, and 1B,
clone isolated by strategy II, were detected in a higher
number of leprosy patients when compared to the nega-
tive controls. Even for the selected clones, a low sensitiv-
ity was observed in the detection of leprosy patients.
Each serum sample was also tested with wild phage by
ELISA in order to evaluate the cross reaction of the
serum with the phage without the insert. The results
show that the reaction of the phage clones was stronger
than that of the wild phage with the positive sera
samples against the phage clones (data not shown), indi-
cating that the reactivity happened exclusively between
the antibodies and the peptides expressed on the surface
of the phages.
The search for similarity of peptide sequences in
Leproma database showed that the peptides selected
mimic mainly proteins in M. leprae (Table 1). However,
the LAM antigen, from which mimotopes can be
isolated, would not be detected by FASTA approach.
Further studies could reveal if those peptides represents
mimotopes of the same antigen or of different antigens.
Comparison of selected mimotopes and the native anti-
gen sequence could lead to a better understanding of
molecular mechanisms that participate in the immune
response and the design of peptides for diagnostic
purposes [19].
Since a humoral response depends on T helper cell re-
sponse, the peptides identified were assessed regarding













































Figure 3 Reactivity of phage clones by ELISA with sera of patients and controls. Microtiter plates were coated with anti-phage antibody
(1:800) and incubated with 2 × 1010 phages/mL followed by the addition of sera (1:100). The detection of the reaction was carried out with
peroxidase conjugated anti-human antibody and OPD as chromogen. Each cell in the table represents an individual. The analysis was performed
in duplicate and the hatched cells represent positive samples. The cut-off value was calculated as the average of the optical density plus twice
the standard deviation obtained with endemic controls.
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response in guinea-pigs sensitized with M. leprae. The
use of guinea-pigs constitutes the animal model used in
delayed-type hypersensitivity tests with M. leprae
antigens, according to description presented previously
[17,20-22]. The intradermal challenge with peptides in
animals previously sensitized with M. leprae induced
delayed-type hypersensitivity. The maximum reading
was observed in 48 hours and, therefore, that time was
considered in the description of the results. No reactions
were detected in animals sensitized with adjuvant as well
as in non-sensitized animals. In the group sensitized
with M. leprae, a DTH reaction was observed with pep-
tide 5A (2/5), peptide 1B (1/5), Mitsuda lepromin (3/5),
and with M. leprae (4/5) (Figure 4). For peptide 1B, the
skin reaction was observed for both 2 and 10 μg doses
with similar sizes - 16.5 mm and 15.5 mm respectively -
whereas for peptide 5A, only the 10 μg dose generated a
response. The two animals that did not respond to
Mitsuda lepromin in 48 hours produced a response
after 72 hours (induration) or 21 days (induration)
after the application of the antigen. The detection of
response with Mitsuda lepromin and the soluble extract
of M. leprae indicate that the animals were sensitized. The
skin reactions observed were erythematous; only one
of the animals immunized with M. leprae, besides the
erythema, also developed a papule as a result of
applying peptide 5A.
The lack of cellular response in other animals is prob-
ably due to the influence of genetic factors involving
genes MHC in the responses to peptides [11,23]. Thus,





M. leprae Sanger ID Description
5A 15 ML2028 Secreted antigen 85-B fbpB
ML0781 Conserved hypothetical protein
ML1135 Probable protoporhyrinogen oxidase hemK homolog
ML0041 Possible secreted protease
ML0053c Possible conserved transmembrane protein
ML2031 Conserved hypothetical protein
ML0213 Possible cell cycle protein MesJ
ML2307c Probable transcriptional regulatory protein WhiB-like whiB4
ML2137 Conserved hypothetical protein
ML1177c Probable conserved liproprotein lprD
6A 12 ML2263c Probable naphthoate synthase menB
ML2028 Secreted antigen 85-B fbpB
ML2030 Probable resuscitation-promoting factor rpfC
ML0053c Possible conserved transmembrane protein
ML0679 Hypothetical protein
ML 0468c Possible conserved integral membrane protein
ML0213 Possible cell cycle protein MesJ
1B 15 ML2028 Secreted antigen 85-B fbpB
ML0097 Secreted antigen 85-A FbpA
ML2485c Possible RNA methyltransferase
ML1195 Isoleucyl-tRNA synthetase IleS
ML2324 2-isopropylmalate synthase leuA
ML2409c Possible cytochrome C-type biogenesis protein ccsA
ML2597 Probable conserved Mce associated protein
ML0455c Conserved hypothetical protein
ML1037c Conserved hypothetical protein
ML0052c Conserved hypothetical protein
ML0130c Probable methyltransferase
ML0369c Conserved hypothetical protein
Potential antigens corresponds to the best scores obtained for each peptide sequence as a query sequence against M. leprae database using FASTA search.
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the mixture of peptides able to recognize different forms
of disease or different genetic aspects could help to over-
come problems of genetic restriction to individual
peptides. Other factors that need to be evaluated are the
dosage and the constitution of the antigen as, for ex-
ample, the conjugation with proteins or modification of
the peptide structure. Differences were found in the
DTH response regarding the dosage of the inoculated
peptide [11,24]. Other studies have tested peptides in
the form of peptide-protein conjugation proteins [25] or
as peptides modified by the addition of fatty acids and
acetylation [26].
Differences in reactivity between phage clones and the
corresponding free peptide have been described previ-
ously [27,28]. When in phage, the sequence could to as-
sume a favorable position to act as binder of antibodies
[29] and therefore this conformation could disappear
when used as synthetic peptides. Likewise, the conform-
ation of the peptide expressed on the phage surface may
discourage recognition by antibodies. Thus, other pep-
tide sequences identified but not included in DTH tests
will be evaluated in future studies. The decision was to
limit the tests to the phage clones that were reactive
with larger number of patients. The selection of
mimotopes was based on seroreactivity and therefore
these mimetic peptides correspond to B cell epitopes.
The strategy of the study was to test whether these
peptides would be able to act as T cell epitopes. Sero-
logical and cellular assays, as proposed initiated this
study may determine whether a peptide can comprise a
serological or T cell test reagent. Tests for humoral im-
mune response benefit lepromatous patients while tests
for evaluation of cellular response will aid in the diagno-
sis of tuberculoid patients.
Lepromin is probably the only skin test antigen that
reflects the individual’s ability to generate a granuloma-
tous response to mycobacterial antigens, as opposed to
the 48–72 hours delayed-type hypersensitivity response
found with tuberculin and other skin tests [7]. In the
lepromin test, the Fernandez reaction is similar to the
reaction produced by tuberculin, since it assesses the
delayed-type hypersentivity of the individual to M. leprae
soluble antigens [22]. In this aspect, the present study
proposes the use of peptides in skin tests to assess the
cellular response, similar to the one captured by the
Mantoux test used in tuberculosis. Besides in vivo stud-
ies, the peptides identified can be assessed in the future
regarding their ability to induce INF-γ production by
peripheral blood mononuclear cells of patients, aiming
to verify whether those reagents allow the detection of
the paucibacillary disease. However, the skin tests are
more feasible and useful as compared to INF-γ produc-
tion assays, since the latter is dependent on the access to
advanced lab facilities and trained personnel, which
limits its use in countries with limited resources [30], a
proposal advocated in the present study. Recently, the
development of a user-friendly assay to detect multiple
cytokines [31] which can make INF-γ detection assays
more accessible and easier to perform was reported.
Synthetic peptides prove to be very attractive to be
used in diagnostic tests or for monitoring the degree of
exposure to leprosy within different communities, or
even an adjunct to leprosy control programs [32], since
they are easy to produce with reproducibility, as well as
high quality and purity control [33]. In addition, syn-
thetic peptides can be easily obtained at a low produc-
tion cost through chemical synthesis. Comparatively,
crude antigens originating from M. leprae are complex
mixtures that carry proteins of humans or animal tissues
in their composition, which may pose biological risks.
Conclusions
Peptides mimotopes were isolated from phage displayed
libraries by screening purified antibodies derived from
leprosy patients’ sera. Our strategy was to evaluate the
ability of mimotopes to induce cellular response in DTH




5A 6A 1B Pool M ML C
1 - - + - - (*) - -
2 - - - - + + -
3 + - - - + + -
4 - - - - - (**) + -


















5A      6A       1B     Pool M      ML       C 
Figure 4 Delayed-type hypersensitivity response induced by
peptides in guinea-pigs. Guinea-pigs were sensitized with 200 μg
M. leprae in Freund’s incomplete adjuvant and - after 30 days - were
inoculated intradermally with peptides and controls. Each group
contained five animals. The result in 48 hours after application of
10 μg peptides, Mistsuda lepromin (M) with 4 × 106 bacilli and 10 μg
soluble extract of M. leprae (ML) is indicated. The peptide pool
contain equimolar amounts of the three peptides. The diameter of
the reaction corresponds to the average of horizontal and vertical
diameters of the erythema. 0.9% NaCl (C) was used as negative
control. * The animal responded after 72 hours. ** The animal
responded after 21 days.
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point to the future design of more effective reagents for
diagnostic purposes.
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